Malaria Vaccines Market secures a jab of rejuvenation with the increasing immunization campaigns against the mosquito-borne diseases

Malaria vaccines have been around for decades, but the actual cure for malaria is still unknown. While there are many vaccines available today to prevent mosquitoes from carrying disease, there is still no known cure for malaria. Because of this, many people choose to take preventative measures and use of malaria prevention products to keep themselves safe.

One of the most popular malaria vaccines is called RTS, or Respiratory Trips and Tracheal, which is manufactured by GlaxoSmithKline. The only approved malaria vaccine as of today is RTS, with the brand name Mosquirax. It has a very low efficiency, takes four injections and requires a series of monitoring to make sure that it is administered correctly. For this reason, many people choose to use other products, like mosquito repellents or other natural preventative measures. In June 2021, the University of Pennsylvania and Acuitas Therapeutics collaborated with the Walter Reed Army Institute of Research and Naval Medical Research Center to create a mRNA-based malaria vaccine. The second most popular malaria vaccines is the trivalent dose of V pneumonovirus (TVP), also produced by GlaxoSmithKline. This vaccine is less effective than RTS; however, it is less likely to cause side effects. The trivalent dose of V pneumonovirus is also released in an aerosol spray, which makes it less likely to be inhaled by susceptible individuals.

Poor supply chains and distribution networks in several malaria-affected emerging economies are limiting the malaria vaccines market expansion in these areas. On the contrary, the growing incidences of malaria, as well as the availability of multiple firms releasing low profit margin vaccines around the globe, are some of the primary reasons driving the malaria vaccines market. Additionally, increasing knowledge of the disease's repercussions, ongoing R&D in this sector, and higher financing from governments in both developing and developed nations are all propelling the malaria vaccines market. In June 2021, Sanaria announced that its PfSPZ vaccine is effective and secure against malaria after their Phase III clinical trial.

Based on geography, the Middle East and Africa (MEA) region is adding to the malaria vaccines market in the line of inadequate financial resources, lack of understanding about the effects of malaria, a lower percentage of medical care, and poorer distribution networks. For instance, in January 2020, the World Health Organization (WHO) reported that over 90 percent of fatalities in Africa were due to malaria. Similarly, due to a large portion of the population in India and Bangladesh residing in the malaria-prone areas, the Asia Pacific region is accommodating the growth aspects of the malaria vaccines market.